Story
Capricor Therapeutics Stock Plummets 68% After FDA Documents Raise Drug Concerns
Summary
Shares of Capricor Therapeutics collapsed by nearly 68%, wiping out over $190 million in value, after FDA briefing documents cast doubt on its lead drug candidate for Duchenne muscular dystrophy. The sell-off followed multiple financial warning signs, including zero revenue and widening losses.
Capricor Therapeutics (NASDAQ: CAPR) shares plummeted 67.7% in a single day, erasing more than $190 million in market capitalization after U.S. Food and Drug Administration documents raised significant concerns about the company's lead drug candidate.
FDA Documents Trigger Sell-Off
The immediate catalyst for the collapse on July 27, 2026, was the release of FDA briefing documents concerning deramiocel, Capricor's investigational therapy for Duchenne muscular dystrophy. According to Investing.com, the documents' tone and lingering uncertainties shattered investor optimism that had been building around the drug's potential approval, leading to the massive sell-off.
Fundamental Warning Signs
The dramatic stock decline was preceded by clear signs of financial distress, despite bullish analyst calls and a cash runway projected into 2027. The company's business model was almost entirely dependent on a single asset without a sustainable revenue stream.
Key red flags included:
Ad- Zero Revenue: Capricor reported $0 in revenue for the first quarter of 2025 and the fourth quarter of 2025, down from $4.9 million and $11.1 million in the respective prior-year periods.
- Widening Losses: The company's net loss more than doubled, growing from $40.5 million in 2024 to $105 million in 2025, with negative earnings per share each quarter.
- Insider Selling: The company's General Counsel sold over $732,000 in shares near the stock's peak, weeks before the collapse.
Disconnect in Market Sentiment
These fundamental weaknesses stood in stark contrast to the optimistic sentiment from many market analysts, who had maintained "Buy" ratings with price targets as high as $60 per share. The sell-off brings the stock price closer to its all-time low of $0.88, set in March 2020.
Capricor's situation underscores the high-stakes risk inherent in clinical-stage biotechnology firms. With its valuation almost entirely tethered to the success of a single drug candidate, any regulatory setback was poised to have an outsized impact on its share price.
Read next
More on Stocks
European Telecoms Face AI-Driven Price Pressure, Bank of America Warns
Bank of America analysts report that while AI agents could increase customer churn for European telecom operators by simplifying price comparisons, the technology also offers powerful tools for sales and personalized customer retention.
ShinyHunters Hackers Renew Attacks on Oracle PeopleSoft Flaw, Google's Mandiant Reports
Google's cybersecurity unit, Mandiant, reports that the hacking group ShinyHunters has resumed and adapted its exploitation of a known vulnerability in Oracle's PeopleSoft enterprise software, targeting organizations that failed to apply a full security patch.
Manulife Stock Climbs, Supported by Cross-Border Investor Optimism
Shares of Manulife Financial gained on Tuesday, buoyed by a strong performance in U.S. markets rather than any specific company news. The stock's move is also supported by a bullish technical posture and positive analyst ratings.
Escondida Union Rejects BHP's Bid to Pause Talks After Fatal Accident
A union at the world's largest copper mine, Escondida, has rejected a request from operator BHP to postpone contract negotiations following a fatal accident earlier this week. The union accused the company of using the tragedy to delay the collective bargaining process.